General MedicationsINTRAVENOUSGeneric

APREPITANT

Standard Dose

130MG/18ML (7.2MG/ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview APREPITANT is listed in Drugs@FDA under application 218754 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient APREPITANT Form and strength INJECTABLE;INTRAVENOUS - 130MG/18ML (7.2MG/ML) Sponsor AZURITY Submission history Latest submission status date: 2024-07-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview APREPITANT is listed in Drugs@FDA under application 218754 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient APREPITANT Form and strength INJECTABLE;INTRAVENOUS - 130MG/18ML (7.2MG/ML) Sponsor AZURITY Submission history Latest submission status date: 2024-07-25 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.